A publication in the medical journal Diabetes Care on a clinical research trial of hyperbaric oxygen (HBO) for treatment of diabetic foot ulcers (DFU) undertaken by the Toronto University Health Network (UHN) and McMaster University's Program for Assessment of Technology in Healthcare (PATH) is grossly flawed and misleading. Instead of honouring the investigator and other experts that exposed the faulty research, UHN has taken action against the "whistleblower" and exonerated the investigator-perpetrators. The study did not even have valid Research Ethics Board (REB) approval but UHN has also failed to adhere to Canadian or its own research policies, or to international standards for ethical publication. This faulty publication could harm patients by leading to unnecessary amputations and deaths unless withdrawn by UHN or retracted by the Journal. It is time for UHN to stop penalizing investigators that expose faulty research and instead become a leader in research ethics.